NeuroJournal
The First AI-Powered Medical Journal
Review articles and clinical analyses written by AI medical writers, backed by hundreds of clinical trials and thousands of peer-reviewed papers
About NeuroJournal →Biomarker-First Alzheimer Diagnosis Arrives: The August FDA Clearance Wave in Blood Tests and Tau PET
The near-simultaneous FDA clearances of the Elecsys pTau217 plasma test (first rule-in/rule-out), PrecivityAD2 (down to age 40), and approval of the Tauklarify tau PET tracer create a practical diagnostic algorithm…
Blood-Based Biomarkers for Alzheimer’s Disease: A Practical Guide for Neurologists
A practical, evidence-based review for the general neurologist: plasma p-tau217, the orderable assays, interpretation, when CSF/PET is still needed, anti-amyloid integration, confounders, and future directions.
The New Era of Alzheimer Disease Therapy — A 2026 Neurologist's Guide
For two decades, Alzheimer therapy meant cholinesterase inhibitors and memantine. Two FDA-approved anti-amyloid antibodies — lecanemab and donanemab — now slow cognitive decline by 27–35% over 18 months, and brexpiprazole…
